Table 2 Characteristics of validation cohort subjects.
From: Different expression of circulating microRNA profile and plasma SP-D in Tibetan COPD patients
Control group | COPD group | P | ||
|---|---|---|---|---|
Age (years) | 66.89 ± 5.86 | 66.89 ± 8.05 | t = 0.119 | 0.960 |
Gender (ratio/%) | X2 = 0.068 | 0.794 | ||
Male | 24 (66.7%) | 25 (63.3%) | ||
Female | 11 (33.3%) | 10 (36.7%) | ||
Smoking history | X2 = 0.516 | 0.473 | ||
Yes | 18 (51.00) | 15 (43.00) | ||
No | 17 (49.00) | 20 (57.00) | ||
Number of acute exacerbations | / | 1.71 ± 0.85 | ||
mMRC | / | 2.63 ± 0.93 | ||
FEV1% predicted (%) | 80.59 ± 7.73 | 45.35 ± 7.70 | t = 19.113 | 0.000 |
FEV1/FVC (%) | 84.67 ± 7.68 | 48.00 ± 12.04 | t = 15.185 | 0.000 |
